Short communication · 28 Feb 2022
Conference abstractPublished 8 Jun 2018
Ascofuranone inhibits lipopolysaccharide-induced inflammatory response via NF-kappaB and AP-1, p-ERK, TNF-α, IL-6 and IL-1β in RAW 264.7 macrophages
SungKyunKwan University, South Korea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The natural fungal compound ascofuranone (5-chloro-3-[(2E, 6E)-7-[(2S)-5, 5-dimethyl-4-oxo-tetrahydrofuran-2-yl]-3-methylocta-2, 6-dienyl]-2, 4-dihydroxy-6-methyl-benzaldehyde, MW 420.93) (AF) is isolated from Ascochyta viciae and has been known to promote cell cycle arrest and inhibit invasion of tumor cells. A structurally similar compound ascochlorin (ASC; MW 404.93) has shown to have anti-inflammatory activity in LPS-stimulated RAW 264.7 macrophages. AF is structurally different than ASC in that AF has a unique dimethyl-oxo-tetrahydrofuran structure, whereas ASC has a unique trimethyl oxocyclohexyl structure. The activity of AF is studied herein to observe the relationship between the anti-inflammatory activities and the different structures of AF and ASC. AF inhibited the production of NO and iNOS and the COX-2 mRNA and protein levels in RAW 264.7 cells in a dose-dependent manner. In addition, AF suppressed mRNA expression levels of inflammatory cytokines such as TNF-Ã?±, IL-6, and IL-1Ã?² when assessed by RT-PCR. When AF (30-50 Ã?¼g/ml) is treated, the nuclear translocation of NF-Ã?ºB, AP-1 (p-c-Jun) from the cytosolic space is clearly downregulated. When phosphorylated, IÃ?ºB maintains the activity of NF-Ã?ºB and this activity was decreased by AF treatment. AF also suppressed the binding of NF-Ã?ºB (p65). Inhibition and degradation of IkBa phosphorylation inhibits nuclear translocation of p65. Immunofluorescence confocal microscopy analysis also revealed that translocation of NF-Ã?ºB and AP-1 (p-c-Jun) was downregulated when AF was treated. AF specifically decreased the expression level of p-ERK, but had no effects on the expression level of p-p38 or p-JNK. Given these results, we suggest that AF has anti-inflammatory effects through targeting p-ERK. These results indicate that AF can be used as a negative regulator of LPS-stimulated nuclear translocation of NF-Ã?ºB and AP-1 (p-cJun) in RAW 264.7 macrophages by specifically targeting p-ERK. Therefore, AF and ASC exert their effects in different ways possibly due to their structural differences that allow AF and ASC to specifically recognize and inhibit their target MAPKs. Our results further suggest that AF could be a useful natural bioactive compound for treating inflammation-mediated pathological diseases
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 8 May 2017
Xanthotoxin, a furanocoumarin compound expresses anti-inflammatory effects through suppression of iNOS, COX-2, TNF-α, and IL-6 via AP-1, NF-κB, and JAK-STAT inactivation in RAW 264.7 cells
Research article · 30 Nov 2020
Enhanced Anti-Inflammatory Effect of Polyherbal Formulation (MKA) Comprising of Three Selected Plants in Lipopolysaccharide (LPS) -Induced Raw 264.7 Macrophage Cell Line
Short communication · 27 Jun 2019
Antiinflammatory Effects of Korean Propolis in Lipopolysaccharide-stimulated RAW 264.7 Macrophages and PMA-induced Mouse Ear Edema
Research article · 21 Sep 2015
Herb Mixture Inhibits Pro-inflammatory Mediators Through the Suppression of JNK and P38 Activation in LPS-Stimulated Raw 264.7 Macrophages
More from this journal
The newest in Journal of Developing Drugs.
Research article · 17 Jul 2026
Effects of a Food-Derived GLP-1 Formula on Endogenous GLP-1 Secretion and Appetite Responses: A Randomized Double-Blind Crossover Study
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Hak Seong Lim”
- BylineArticles whose byline prints “Sun-Hyung Ha”
- BylineArticles whose byline prints “Jun young Park”
- BylineArticles whose byline prints “Fukushi Abekura”
- BylineArticles whose byline prints “Cheorl-Ho Kim”

